Back to Search Start Over

Methazolamide Plus Aminophylline Abrogates Hypoxia-Mediated Endurance Exercise Impairment.

Authors :
Scalzo, Rebecca L.
Binns, Scott E.
Klochak, Anna L.
Giordano, Gregory R.
Paris, Hunter L.R.
Sevits, Kyle J.
Beals, Joseph W.
Biela, Laurie M.
Larson, Dennis G.
Luckasen, Gary J.
Irwin, David
Schroeder, Thies
Hamilton, Karyn L.
Bell, Christopher
Source :
High Altitude Medicine & Biology. Dec2015, Vol. 16 Issue 4, p331-342. 12p.
Publication Year :
2015

Abstract

Scalzo, Rebecca L., Scott E. Binns, Anna L. Klochak, Gregory R. Giordano, Hunter L.R. Paris, Kyle J. Sevits, Joseph W. Beals, Laurie M. Biela, Dennis G. Larson, Gary J. Luckasen, David Irwin, Thies Schroeder, Karyn L. Hamilton, and Christopher Bell. Methazolamide plus aminophylline abrogates hypoxia-mediated endurance exercise impairment. High Alt Med Biol 16:331-342, 2015.-In hypoxia, endurance exercise performance is diminished; pharmacotherapy may abrogate this performance deficit. Based on positive outcomes in preclinical trials, we hypothesized that oral administration of methazolamide, a carbonic anhydrase inhibitor, aminophylline, a nonselective adenosine receptor antagonist and phosphodiesterase inhibitor, and/or methazolamide combined with aminophylline would attenuate hypoxia-mediated decrements in endurance exercise performance in humans. Fifteen healthy males (26 ± 5 years, body-mass index: 24.9 ± 1.6 kg/m2; mean ± SD) were randomly assigned to one of four treatments: placebo ( n = 9), methazolamide (250 mg; n = 10), aminophylline (400 mg; n = 9), or methazolamide (250 mg) with aminophylline (400 mg; n = 8). On two separate occasions, the first in normoxia (FIO2 = 0.21) and the second in hypoxia (FIO2 = 0.15), participants sat for 4.5 hours before completing a standardized exercise bout (30 minutes, stationary cycling, 100 W), followed by a 12.5-km time trial. The magnitude of time trial performance decrement in hypoxia versus normoxia did not differ between placebo (+3.0 ± 2.7 minutes), methazolamide (+1.4 ± 1.7 minutes), and aminophylline (+1.8 ± 1.2 minutes), all with p > 0.09; however, the performance decrement in hypoxia versus normoxia with methazolamide combined with aminophylline was less than placebo (+0.6 ± 1.5 minutes; p = 0.01). This improvement may have been partially mediated by increased SpO2 in hypoxia with methazolamide combined with aminophylline compared with placebo (73% ± 3% vs. 79% ± 6%; p < 0.02). In conclusion, coadministration of methazolamide and aminophylline may promote endurance exercise performance during a sojourn at high altitude. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15270297
Volume :
16
Issue :
4
Database :
Academic Search Index
Journal :
High Altitude Medicine & Biology
Publication Type :
Academic Journal
Accession number :
111800126
Full Text :
https://doi.org/10.1089/ham.2015.0066